Nautilus Biotechnology (NAUT) Return on Capital Employed (2025 - 2026)
Nautilus Biotechnology (NAUT) posted Return on Capital Employed of 21.73% for Q2 2026, down 134.94% sequentially from 9.25% in Q2 2025, and down 1248.0% YoY from 1.89% in Q2 2025.
Nautilus Biotechnology (NAUT) Return on Capital Employed (2025 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Return on Capital Employed for 2 years, with the latest figure at 21.73% in Q2 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Nautilus Biotechnology | 114.43 Mn | 114.43 Mn | 175,000.00 | -21.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.73% |
| Jun 30, 2025 | -9.25% |